Survival after treatment of advanced renal cell carcinoma (RCC) with high-dose interleukin-2 (rIL-2) or vinblastine (VLB) [2]

R. Sorio, E. Galligioni, D. Crivellari, R. Talamini, S. Monfardini

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)306-307
Number of pages2
JournalAnnals of Oncology
Volume6
Issue number3
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Survival after treatment of advanced renal cell carcinoma (RCC) with high-dose interleukin-2 (rIL-2) or vinblastine (VLB) [2]. / Sorio, R.; Galligioni, E.; Crivellari, D.; Talamini, R.; Monfardini, S.

In: Annals of Oncology, Vol. 6, No. 3, 1995, p. 306-307.

Research output: Contribution to journalArticle

Sorio, R. ; Galligioni, E. ; Crivellari, D. ; Talamini, R. ; Monfardini, S. / Survival after treatment of advanced renal cell carcinoma (RCC) with high-dose interleukin-2 (rIL-2) or vinblastine (VLB) [2]. In: Annals of Oncology. 1995 ; Vol. 6, No. 3. pp. 306-307.
@article{25f4ee4174a0400689f8bab79cffbea2,
title = "Survival after treatment of advanced renal cell carcinoma (RCC) with high-dose interleukin-2 (rIL-2) or vinblastine (VLB) [2]",
author = "R. Sorio and E. Galligioni and D. Crivellari and R. Talamini and S. Monfardini",
year = "1995",
language = "English",
volume = "6",
pages = "306--307",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Survival after treatment of advanced renal cell carcinoma (RCC) with high-dose interleukin-2 (rIL-2) or vinblastine (VLB) [2]

AU - Sorio, R.

AU - Galligioni, E.

AU - Crivellari, D.

AU - Talamini, R.

AU - Monfardini, S.

PY - 1995

Y1 - 1995

UR - http://www.scopus.com/inward/record.url?scp=0028957652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028957652&partnerID=8YFLogxK

M3 - Article

C2 - 7612500

AN - SCOPUS:0028957652

VL - 6

SP - 306

EP - 307

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -